Johnson & Johnson has been embroiled in numerous legal battles surrounding its marketing of its antipsychotic drug Risperdal. The company is alleged to have paid millions of dollars in kickbacks to pharmaceutical giant Omnicare to influence Risperdal sales to nursing home residents.